Stephen E. Fawell
Bioscience Research(US)AstraZeneca (Brazil)(BR)BioScience Laboratories (United States)(US)AstraZeneca (United States)(US)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Melanoma and MAPK Pathways, Immune cells in cancer, PARP inhibition in cancer therapy, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling(2009)2,068 cited
- → Tat-mediated delivery of heterologous proteins into cells.(1994)1,219 cited
- → Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors(2013)676 cited
- → Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor(1990)613 cited
- → Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia(2018)480 cited
- → Challenges and Opportunities in Cancer Drug Resistance(2020)419 cited